Production (Stage)
Relmada Therapeutics, Inc.
RLMD
$0.7085
-$0.0415-5.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.56M | -18.66M | -21.73M | -17.77M | -21.83M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.26M | 6.97M | 7.52M | 7.13M | 8.19M |
| Change in Net Operating Assets | -4.77M | 2.89M | -2.45M | -2.62M | 599.80K |
| Cash from Operations | -18.07M | -8.80M | -16.66M | -13.26M | -13.04M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.36M | 11.35M | 16.14M | 14.01M | 10.06M |
| Cash from Investing | 15.36M | 11.35M | 16.14M | 14.01M | 10.06M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 0.00 | 0.00 | 0.00 | 246.70K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -172.50K | -89.60K | 0.00 | -25.00K |
| Cash from Financing | -- | -172.50K | -89.60K | 0.00 | 221.70K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.71M | 2.37M | -602.50K | 751.20K | -2.76M |